Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

This study is looking for both women and men, aged 18 or older, who have been diagnosed with early-stage, operable HER2-positive breast cancer. Your cancer must be confirmed as HER2-positive by special tests.

To join, your overall health should be good, meaning you can carry out your daily activities without much trouble. Your latest scans or tests should show your tumour is a certain size, typically at least 1.5 centimetres. Also, your blood tests must show that your kidneys, liver, and blood cell counts are working well enough to safely receive the study treatments.

You cannot have had any chemotherapy, radiation, or anti-HER2 treatments for your breast cancer before this study. If you have other serious health conditions that might interfere with the study treatments, you may not be able to participate. The study team will review all your medical information carefully to see if you're a good fit.

If you join this study, you'll be assigned by chance to one of two main groups. One group will get Herceptin and Perjeta along with chemotherapy (docetaxel and carboplatin). The other group will receive Herceptin and Perjeta, possibly with hormone therapy depending on your cancer type. You'll have special scans (PET/CT scans) at the start and again after about two months to see how your tumour is responding. Depending on these scan results, your treatment plan might be adjusted.

All treatments will be given over several months before your surgery. After surgery, you'll continue with Herceptin and Perjeta for up to 18 cycles (about a year), plus any other standard treatments like hormone therapy or radiotherapy, as advised by your doctors. You'll have regular follow-up appointments and scans to monitor your health and ensure the treatment is effective. The total duration of the active treatment phase can be around a year and a half, with follow-up for three years.